How to use Eltrombopag

Eltrombopag is an oral thrombopoietin receptor agonist, commonly used to treat chronic immune thrombocytopenia (ITP), severe aplastic anemia and other diseases. By stimulating thrombopoietin receptors, eltrombopag promotes bone marrow megakaryocyte division and maturation, ultimately increasing platelet production. To ensure therapeutic effectiveness and minimize side effects, correct medication administration is important.

1. Dosage and usage

The recommended dose of eltrombopag is usually 1 oral dose once daily. In patients with chronic immune thrombocytopenia (ITP), the initial adult dose is usually 50 mg once daily, particularly in patients who have not received other treatment. Your doctor may adjust the dose based on platelet count and individual response. Depending on the patient's condition, the dose of eltrombopag can be adjusted from 50 mg to 75 mg, 100 mg or higher. It is generally recommended to monitor platelet counts weekly and adjust dosage as needed. The goal is to maintain platelet counts between 50,000/μL and 200,000/μL.

For other types of thrombocytopenia, such as severe aplastic anemia, specific adjustments in dosage need to be determined based on the individual patient response and severity of illness. For these patients, the dosage range may be broader.

2. How to take

Eltrombopag should be taken orally 1 hour before a meal or 2 hours after a meal. Because food can affect the absorption of eltrombopag, especially iron-rich foods can reduce the absorption efficiency of eltrombopag. Therefore, patients are advised to take the medication on an empty stomach to ensure optimal absorption of the medication.

Eltrombopag should be swallowed whole and not chewed, crushed, or broken. That's because Eltrombopag's drug shell helps control how quickly the drug is released. If you are unable to swallow the entire tablet, consider talking to your doctor about alternatives, such as adjusting the dosage form or delivery method.

3. Interactions with other drugs

Eltrombopag may interact with other drugs, especially those that affect drug metabolism. Certain medications, such as antacids, iron-containing supplements, and calcium channel blockers, can decrease the absorption of eltrombopag. Therefore, taking eltrombopag with these drugs should be avoided. If a patient needs to take these drugs at the same time, it is usually recommended to take them at different times and to ensure that eltrombopag is taken on an empty stomach.

In addition, eltrombopag may interact with some drugs that affect liver enzymes (such asCYP450). Therefore, before starting treatment, patients should inform their doctor about all medications they are taking, including over-the-counter and herbal medicines.

4. Adjust dosage

The patient's platelet count needs to be monitored regularly. The dose may need to be reduced if platelet counts increase to the target range or excessively high platelet counts occur. Common dose adjustment options include reducing the dose or discontinuing the drug until platelet counts fall back to a safe range.

5. Treatment Course and Discontinuation

Treatment with eltrombopag is usually long-term, but the specific course of treatment depends on the patient's condition and response. For some patients, long-term maintenance therapy may be needed. For other patients, the goal of treatment is to maintain platelet counts through dose adjustments or drug discontinuation. If a patient fails to achieve ideal platelet levels or develops drug resistance during treatment, a change in treatment regimen may need to be considered.

6. Side Effect Management

When taking Eltrombopag, patients may experience some side effects, such as headache, nausea, dry mouth, upper respiratory tract infection, etc. More serious side effects include liver function damage, thrombosis, anemia, etc. Therefore, patients need to regularly monitor liver function and blood indicators during treatment. If serious adverse reactions occur, they should be reported to the doctor promptly and treatment adjustments should be made.

Eltrombopag is an effective drug for the treatment of thrombocytopenia, but its use requires strict compliance with the doctor's recommendations and regular monitoring of indicators such as platelet count and liver function to ensure safety and efficacy. Patients should avoid taking it with food or drugs that may affect drug absorption, and take it at the prescribed time and method.